Stock Evaluator: Mustang Bio, Inc. (MBIO)

Mustang Bio, Inc. MBIO

$0.38 -0.01 -2.56%
November 18, 2026 4:00:00 PM EST November 10, 2021 Volume: 8,840
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.

Commentary & Analysis


Financial Summary

Share Statistics MBIO Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $2.9 $213.9 3%
Shares Out (Mil) 6.7 55.4 17%
Institutional Ownership 99.8% 93.3% 94%
Float (Mil) 6.2 40.6 14%
Beta 2.20 0.98 94%
Avg Daily Volume (000s) 43 597 28%
Price Change
(52-week)
(67.2%) 40.9% 13%
Growth MBIO Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 13.2% na
Net Income (5yr) 49.9% (10.7%) 94%
EPS (5yr) 78.5% 15.5% 98
Dividends (5yr) na 0.0% na
Cash Flow (5yr) (66.7%) (15.7%) 3%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates na na na
Current EPS na na na
Month Ago EPS na na na
# Rev Up na na na
# Rev Down na na na
Three Months Ago EPS na na na
Year/Year Chg na na na
Financials MBIO Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) na $39 na
Net Income (TTM) (Mil) ($4) ($44) 34%
EPS (TTM) ($0.529) ($1.400) 26%
Operating Cash Flow (TTM) (Mil) ($5) ($34) 26%
Net Cash Flow (TTM) (Mil) na $-0 na
Long-Term Debt (Q1) (Mil) $0 $4 0%
Enterprise Value (Q1) (Mil) ($11) $135 2%
Valuation MBIO Industry
Median
Percentile
(All Stocks)
P/B 0.44 1.97 10%
P/E na 17.6 na
Dividend Yield na 0.0% na
PEG (5yr hist) na 0.8 na
Ratios MBIO Industry
Median
Percentile
(All Stocks)
Gross Margin na 67.9% na
Net Margin na (50.8%) na
ROA (20.7%) (47.5%) 19%
ROE (43.1%) (51.9%) 17%
Liabilities to Assets 55.1% 29.7% 48%
F-Score 0 3 0%

Mustang Bio, Inc. did not pass any screens on 11/18/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors